The therapy is intended for the treatment of non-operable critical limb ischemia. The therapy is currently in clinical trials. “We experienced an 82 percent major amputation free rate in the intent-to-treat patients, and significant reductions in hard clinical endpoints including VAS pain scores and a meaningful improvement in the six minute walk test,” said Ken Harris, president of Cesca Therapeutics.
Cesca Therapeutics focuses on the research, development and commercialization of autologous cell-based therapeutics for use in regenerative medicine.
More articles on devices:
Medtronic keeps getting bigger — acquires Sapiens Steering Brain Stimulation for $200M
Amedica names Dr. B. Sonny Bal chairman of the board
Spine Pain Management names David Spencer CIO
